GFS Advisors LLC Acquires 11,655 Shares of Sanofi (NASDAQ:SNY)

GFS Advisors LLC grew its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 1,017.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,800 shares of the company's stock after acquiring an additional 11,655 shares during the quarter. GFS Advisors LLC's holdings in Sanofi were worth $738,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in shares of Sanofi during the 2nd quarter worth approximately $13,725,000. Mount Yale Investment Advisors LLC raised its stake in Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company's stock valued at $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC raised its stake in Sanofi by 18.9% in the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company's stock valued at $9,216,000 after acquiring an additional 30,115 shares during the period. Sei Investments Co. raised its stake in Sanofi by 9.3% in the 1st quarter. Sei Investments Co. now owns 554,028 shares of the company's stock valued at $26,926,000 after acquiring an additional 47,297 shares during the period. Finally, Janney Montgomery Scott LLC raised its stake in Sanofi by 10.4% in the 1st quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company's stock valued at $14,951,000 after acquiring an additional 29,082 shares during the period. Institutional investors and hedge funds own 10.04% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Argus increased their price target on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, July 26th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research note on Tuesday, September 17th. Finally, StockNews.com raised Sanofi from a "buy" rating to a "strong-buy" rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY traded up $0.39 on Friday, reaching $53.27. The stock had a trading volume of 1,381,542 shares, compared to its average volume of 2,109,692. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a fifty day moving average of $55.92 and a two-hundred day moving average of $52.05. Sanofi has a 1-year low of $45.00 and a 1-year high of $58.97. The company has a market cap of $135.19 billion, a P/E ratio of 27.18, a price-to-earnings-growth ratio of 1.35 and a beta of 0.61.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. The firm had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company's revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.55 EPS. On average, equities research analysts anticipate that Sanofi will post 4.27 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.